These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37850684)

  • 1. Prediction of molecular interaction of Phosphodiesterase 10A inhibition by natural compounds: insights from structure-based screening and molecular dynamics simulations.
    Ali Alshehri S; Alsayari A; Wahab S; H Alqarni M; Sweilam SH; Khalid M
    J Biomol Struct Dyn; 2024; 42(22):12596-12607. PubMed ID: 37850684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders.
    Sharma B; Bhattacherjee D; Zyryanov GV; Purohit R
    J Biomol Struct Dyn; 2023 Nov; 41(19):9424-9436. PubMed ID: 36336960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
    Al-Nema M; Gaurav A; Akowuah G
    Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.
    Fan HT; Guo JF; Zhang YX; Gu YX; Ning ZQ; Qiao YJ; Wang X
    Mol Med Rep; 2018 Jan; 17(1):388-393. PubMed ID: 29115449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR.
    Codutti L; Grimaldi M; Carlomagno T
    J Chem Inf Model; 2017 Jun; 57(6):1488-1498. PubMed ID: 28569061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
    Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
    Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
    Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
    Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
    Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
    Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors.
    Jokinen EM; Postila PA; Ahinko M; Niinivehmas S; Pentikäinen OT
    Chem Biol Drug Des; 2019 Oct; 94(4):1799-1812. PubMed ID: 31260165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus.
    Samantaray M; Pattabiraman R; Murthy TPK; Ramaswamy A; Murahari M; Krishna S; Kumar SB
    J Biomol Struct Dyn; 2024 Oct; 42(16):8505-8522. PubMed ID: 37646701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches.
    Halder AK; Amin SA; Jha T; Gayen S
    SAR QSAR Environ Res; 2017 Mar; 28(3):253-273. PubMed ID: 28322591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
    Amin HS; Parikh PK; Ghate MD
    Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.
    Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method.
    Kjellgren ER; Glue OE; Reinholdt P; Meyer JE; Kongsted J; Poongavanam V
    J Mol Graph Model; 2015 Sep; 61():44-52. PubMed ID: 26188794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.
    Huang J; Hu B; Xu Z; Ye Y; Wang H; Wang S; Liu Z; Wang J
    J Mol Model; 2021 Dec; 28(1):9. PubMed ID: 34907481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
    Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
    J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring natural compound, Panicutine as leucine-rich repeat kinase 2 inhibitor against Parkinson's disease: a structure-guided approach.
    Majrashi TA; Wahab S; Almoyad MAA; Alkhathami AG; Alshahrani MY
    J Biomol Struct Dyn; 2024; 42(22):12154-12163. PubMed ID: 37837424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring natural products as multi-target-directed drugs for Parkinson's disease: an
    Boulaamane Y; Touati I; Goyal N; Chandra A; Kori L; Ibrahim MAA; Britel MR; Maurady A
    J Biomol Struct Dyn; 2024; 42(20):11167-11184. PubMed ID: 37753798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.